FDA Approves Oral Bafiertam, Similar to Tecfidera for Relapsing MS - No Launch Date Yet
May 04, 2020
May 04, 2020
NEW YORK, May 4 -- The National Multiple Sclerosis Society issued the following news:
The U.S. Food and Drug Administration has approved Bafiertam(TM) (monomethyl fumarate, Banner Life Sciences) as an oral disease-modifying therapy for people with relapsing forms of MS. Bafiertam (pronounced bah"feer'tam) is similar to Tecfidera(R) and Vumerity(TM) but has a distinct chemical structure. No launch date has been announced yet.
* Relapsing forms of MS includes people . . .
The U.S. Food and Drug Administration has approved Bafiertam(TM) (monomethyl fumarate, Banner Life Sciences) as an oral disease-modifying therapy for people with relapsing forms of MS. Bafiertam (pronounced bah"feer'tam) is similar to Tecfidera(R) and Vumerity(TM) but has a distinct chemical structure. No launch date has been announced yet.
* Relapsing forms of MS includes people . . .